Stay updated on Nivolumab Relatlimab in Metastatic Melanoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Relatlimab in Metastatic Melanoma Clinical Trial page.

Latest updates to the Nivolumab Relatlimab in Metastatic Melanoma Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check17 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1, and this update appears to be a version change that does not affect study data or user actions; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check25 days agoChange DetectedA new 'Show glossary' option is now available and the footer displays 'Revision: v3.4.0'. The study dates section adds 'Last Update Submitted that Met QC Criteria' and capitalization for No FEAR Act items was adjusted.SummaryDifference0.2%

- Check39 days agoChange DetectedThe page shows a minor version update: Revision: v3.3.4 added and Revision: v3.3.3 removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check60 days agoChange DetectedAdded a new Locations section listing Tennessee (Nashville, Vanderbilt-Ingram Cancer Center) as a study site. Removed the separate Tennessee Locations entry in the footer.SummaryDifference0.2%

- Check89 days agoChange DetectedThe page now shows Revision: v3.3.2 instead of v3.2.0, with no changes to the study details.SummaryDifference0.1%

Stay in the know with updates to Nivolumab Relatlimab in Metastatic Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Relatlimab in Metastatic Melanoma Clinical Trial page.